Acute management of bipolar disorders

Australian Prescriber

Volumn 31, Issue 3, 2008, Pages 73-76

  Singh, Ajeet ^a   Berk, Michael ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Depression; Hypomania; Management; Mania

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; COPING BEHAVIOR; DEPRESSION; ELECTROCONVULSIVE THERAPY; HOSPITALIZATION; HUMAN; MENTAL INSTABILITY; MONOTHERAPY; PHYSICIAN; REVIEW; RISK ASSESSMENT; SOCIAL PSYCHOLOGY;

EID: 45749091439     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2008.042     Document Type: Review

References (14)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602 .
2. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 2000;61(Suppl 9):47-51.
3. Access Economics. Bipolar disorder: costs. An analysis of the burden of bipolar disorder and related suicide in Australia. Melbourne: Access Economics, for SANE Australia; 2003. http://www.accesseconomics.com.au/publicationsreports/ reports.php [cited 2008 May 13]
4. Berk M, Dodd S, Callaly P, Berk L, Fitzgerald P, de Castella AR, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord 2007;103:181-6.
5. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Press; 2000.
7. Pyle DI, Mitchell PB. Maintenance treatments for bipolar disorders. Aust Prescr 2007;30:70-3.
8. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al; CANMAT guidelines group. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8:721-39.
9. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004;38:280-305.
10. Nasrallah HA, Ketter TA, Kalali AH. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J Affect Disord 2006;95:69-78.
11. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007;115:12-20.
12. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006;11:227-40.
13. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22.
14. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-9.